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Video-Assisted Thoracic Surgery Lobectomy for Non-small
Cell Lung Cancer in Patients with a Charlson Comorbidity
Index Score of Two or More
Ryoichi Nakanishi, MD, PhD, Toshihiro Yamashita, MD, and Soichi Oka, MD
Introduction: We evaluated the feasibility and safety of the video-
assisted thoracic surgery (VATS) lobectomy for non-small cell lung
cancer (NSCLC) in patients with comorbidity.
Methods: Between April 2000 and December 2006, a prospective
database of 58 consecutive patients undergoing a VATS lobectomy
for NSCLC, who had a Charlson comorbidity index score of 2 or
more, was retrospectively analyzed. The demographic, periopera-
tive, histopathologic, and outcome variables, including the recur-
rence and survival, were assessed.
Results: The VATS lobectomy was successfully performed in 57
patients (16 women and 41 men; median age, 70 years). Twenty-
three patients (40.4%) were aged 75 years or older. The total score
of the Charlson comorbidity index was as follows: 2 in 26 patients,
3 in 13 patients, 4 in 12 patients, 5 in five patients, and 6 in one
patient. None of the patients required a blood transfusion during
surgery or during the postoperative course. We observed no intra-
operative or in-hospital deaths, and no complications occurred in the
45 patients (78.9%). At a median follow-up of 34 months, a
recurrence was observed in five patients who had advanced stages:
a local recurrence in one and a distant recurrence in four. The overall
5-year survival rates for postoperative stage IA (n 25) and IB (n
16) were 100% and 94%, respectively.
Conclusions: We believe that a VATS lobectomy is a feasible and
safe procedure for NSCLC in patients with comorbidity because this
modality demonstrates an acceptable morbidity and a favorable
oncologic outcome.
Key Words: Video-assisted thoracic surgery (VATS), Non-small
cell lung cancer, Lobectomy, Comorbidity.
(J Thorac Oncol. 2010;5: 56–61)
The number of surgical candidates with comorbidity in-creases as the aged population increases. Especially in
patients with lung cancer, comorbidity is more frequently
observed due to the large number of patients who smoke.
Many investigators have reported that the comorbidity is one
of the important predictors of survival in patients with non-
small cell lung cancer (NSCLC).1–4 Furthermore, the surgical
treatment for NSCLC in patients with comorbid diseases
always poses a dilemma regarding whether to perform a
limited resection to achieve an uneventful recovery or an
curative resection to achieve an oncologic cure.
Recently, many video-assisted thoracic surgery (VATS)
lobectomies have been performed as minimally invasive sur-
gery, since the earliest reports of a videoendoscopic pulmonary
lobectomy for lung cancer were published a decade and a half
ago.5 This treatment modality seems to be the preferred
method for patients with comorbidity because it provides the
benefits of decreased pain-related morbidity6 while also
achieving oncologic efficacy for early NSCLC.7 Although
evidence in the literature is increasing that a VATS lobec-
tomy may be a safe and efficacious procedure for
NSCLC,8–15 such evidence regarding patients with comor-
bidity is still sparse.
To resolve the dilemma regarding the optimal surgical
treatment for patients with comorbidity, a VATS lobectomy
has always been applied to such patients with NSCLC at our
hospital.16 The purpose of this study is to evaluate the
feasibility and safety of performing a VATS lobectomy for
NSCLC in patients with comorbidity.
PATIENTS AND METHODS
Patients
Between April 2000 and December 2006, 160 patients
underwent a VATS major lung resection for NSCLC at our
hospital. The indications for a VATS major lung resection
were based on the standard criteria for an open thoracotomy,
including tumors up to 6 cm in diameter. The preoperative
staging included a chest roentgenogram, computed tomo-
graphic scan of the body with intravenous contrast, flexible
bronchoscopy, brain magnetic resonance, and bone scintigraphy.
Mediastinoscopy was not routinely performed, whereas positron
emission tomography was frequently used. The status of comor-
bidity was objectively assessed using the Charlson comorbidity
index (CCI), which takes into account both the number and
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seriousness of comorbid diseases. Components of the weighted
index are published in Charlson’s manuscript.17 The assigned
weights for each comorbid condition that a patient has was
estimated, and the sum of the weighted index of the patient
was calculated. The patients with comorbidity were identified
as those with total score of the CCI of 2 or more, which has
been reported to be closely associated with the morbidity and
mortality.3,4
Of the 160 patients, a prospective electronic database of
58 consecutive patients (36.3%) undergoing a VATS lobec-
tomy for NSCLC, with the CCI score of 2 or more, was
retrospectively analyzed. This series includes consecutive
patients for whom the preoperative intention was to perform
a VATS major pulmonary resection including a lobectomy or
a bilobectomy. Any patient demonstrating primary NSCLC
with direct invasion of the vessels, main bronchus, or sur-
rounding organs was excluded. The Institutional Review
Board of Clinical Research of our hospital ethically approved
this study, and informed consent for this prospective study
was obtained from all patients.
Surgical Technique
Under single-lung anesthesia, four incisions were used
in the majority of the patients in this series. A utility thora-
cotomy was placed in the third or fourth intercostal space and
consisted of a 5- to 7-cm incision. The remaining three
incisions for the 5.5-mm or 12-mm trocars were made. The
pulmonary vessels and bronchi were individually divided and
an extensive dissection of the mediastinal lymph nodes was
performed, as previously reported.16 All VATS procedures
were performed without the use of a rib spreader.
Data Acquisition and Follow-Up
The demographic, perioperative, histopathologic, and
outcome variables, including recurrence and survival, were
analyzed. In addition, a subset analysis was performed that
excluded minor comorbidities such as a history of a prior
cancer, stage I chronic obstructive pulmonary disease
(COPD), and a history of congestive heart failure showing an
ejection fraction of more than 40% from the CCI because
these conditions probably have little effect on morbidity or
mortality. The CCI score of these conditions was regarded as
0, and then the patients with total score of the CCI of 2 or
more were studied. The operative mortality included all
patients who died within the first 30 days after surgery or
during the hospitalization, regardless of the length of stay.
The postoperative morbidity included all patients who suf-
fered complications during the hospitalization and after dis-
charge from the hospital. The complete follow-up data were
obtained from the records of the post discharge visits, from
the regular radiographic follow-up, and from telephone inter-
views. Computed tomographic scans of the body were ob-
tained in all patients at 12 months postoperatively and there-
after at yearly intervals. Recurrence was defined as local
when the disease recurred in the hilar or mediastinal lymph
nodes, in the pleural space, or at the surgical margins.
Recurrence was defined as distant when the disease devel-
oped in a separate lobe or in the contralateral lung, in addition
to a remote metastatic disease.
Statistical Analysis
Standard descriptive statistics and Kaplan-Meier sur-
vival analyses were used. The 2 test and Fisher’s exact test
were used to test whether relationships existed between the
nominal variables. The continuous variables were analyzed
by the Mann-Whitney U test. Comparisons of the survival
were made using the log-rank test. The differences were
considered to be statistically significant when the p value was
less than 0.05.
RESULTS
Demographic and Comorbidity Data
One of the 58 consecutive patients with the CCI score
of 2 or more was excluded from this study because the patient
was converted from VATS to an open thoracotomy to per-
form angioplasty of the pulmonary artery. The subjects in-
cluded 16 women (28.1%) and 41 men (71.9%). The median
age was 70 years (range, 52–90); 23 patients (40.4%) were
aged 75 years or older, and 10 (17.5%) of those were aged 80
years or older. A smoking history was present in 41 patients
(median pack-year of tobacco smoking: 42). The preoperative
clinical stage of NSCLC included stage IA in 28, IB in 20,
IIB in six and IIIA in three patients.
The comorbid conditions are listed in Table 1. The
malignant disease group included 10 patients with colorectal
cancer, nine patients with gastric cancer, four patients with
prostatic cancer, nine patients with other cancers, and one
patient with malignant lymphoma. Twenty-nine of 33 pa-
tients with previous disease of malignancy (87.9%) had an
early-stage NSCLC, and the ratio was slightly more than that
of the remaining 24 patients without prior malignancy. The
patients with chronic pulmonary disease included 14 patients
with COPD, four patients with both COPD and restrictive
pulmonary disease such as tuberculous pleuritis, three pa-
tients with restrictive pulmonary disease, two patients with
both COPD and interstitial lung disease such as interstitial
pneumonia, two patients with interstitial lung disease, two
patients with bronchial asthma requiring steroid medication,
and one patient with both COPD and bronchial asthma. The
21 patients with COPD had the following stages: stage I
(80  predicted % forced expiratory volume in 1 second
[FEV1]) in 13 patients, stage II (50  predicted % FEV1
TABLE 1. Comorbidity (n  57)
Comorbid Conditions (Assigned
Weights for Diseases) No. of Patients (%)
Any malignant tumor or lymphoma (2) 33 (57.9)
Chronic pulmonary disease (1) 28 (49.1)
Cerebrovascular disease (1) 18 (31.6)
Diabetes (1) 13 (22.8)
Ulcer disease (1) 9 (15.8)
Myocardial infarct (1) 7 (12.3)
Mild liver disease (1) 7 (12.3)
Peripheral vascular disease (1) 4 (7.0)
Congestive heart failure (1) 4 (7.0)
Hemiplegia (2) 1 (1.8)
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80) in seven patients, and stage III (30  predicted %
FEV1 50) in one patient.18 Four patients who had a diag-
nosis of congestive heart failure showed 40 to 50% of cardiac
ejection fraction as determined by echocardiography. The
total score of the CCI was as follows: 2 in 26 patients, 3 in 13
patients, 4 in 12 patients, 5 in five patients, and 6 in one
patient.
Perioperative and Histopathologic Data
The thoracoscopic exploration showed a broad adhe-
sion in 10 patients (17.5%) and a broad fused fissure in 43
patients (75.4%). In particular, seven patients (12.3%) pre-
sented with a severe pleural adhesion and fused major fissure.
The treatment modality was a lobectomy in 54 patients and a
bilobectomy in three patients. The distribution of the lobec-
tomies was as follows: right upper lobe in 16 patients, right
lower lobe in 15, right upper and middle lobe in one, right
middle and lower lobe in two, left upper lobe in 13, and left
lower lobe in 10. The combined resections performed were as
follows: the involved ipsilateral lung in two patients, a part of
the contralateral lung in one patient, and the involved parietal
pleura in one patient. The median number of total dissected
nodes (only mediastinal nodes) was 33 (16) nodes. The
median operation time was 305 minutes, and the bleeding
volume was 114 ml. No patients required a blood transfusion
during the surgery or the postoperative course. The median
chest tube duration was 2 days, and the median length of
hospitalization was 12 days (range, 7–57 days). There were
no differences in hospital stay between the lower (2–3) and
higher (4–6) groups of CCI score and among types of
comorbidity.
The histologic types of the primary NSCLC resected
included adenocarcinoma in 38 patients (including one pa-
tient with bronchioloalveolar carcinoma), squamous cell car-
cinoma in 18, and adenosquamous carcinoma in one. The
postoperative stages were as follows: IA in 25, IB in 16, IIA
in one, IIB in two, IIIA in six, and IIIB in seven patients. All
surgical margins were clear, and the most frequent histologic
subtype was adenocarcinoma (66.7%). Three patients with
stage IIIA disease preoperatively had a single N2 station
consisting of subcarinal node enlargement. Because the in-
creasing experience with the VATS lobectomy has allowed
an expansion of the indications for lobectomy, this series
included nine patients (15.8%) with a preoperative stage II
or greater NSCLC. The additional patients with stage IIIA
postoperatively had pathologic N2 disease, which was
found after surgery. Seven patients with stage IIIB post-
operatively were found to have metastasis within the same
resected lobe (T4).
Morbidity and Mortality
There were no complications in 45 patients (78.9%),
and 14 complications were observed in the remaining 12
patients (21.1%) (Table 2). Three of five patients (60.0%)
who presented with prolonged air leaks had some pulmonary
comorbidity, such as COPD and/or restrictive pulmonary
disease, whereas all patients who presented with sputum
retention had some pulmonary comorbidity. There were no
differences in development of complication between the
lower (2–3) and higher (4–6) groups of CCI score (17.9%
versus 27.8%, respectively; p  0.4893). There were no
intraoperative or in-hospital deaths.
Recurrence and Survival
No patients were lost to follow-up. A total of one local
recurrence and four distant recurrences have been identified in
the follow-up period. Patients with postoperative stage I (A and
B) showed neither local nor distant recurrence. The local recur-
rences included a subcarinal lymphadenopathy in one patient
with postoperative stage IIIA who underwent a right upper
lobectomy. There were no instances of wound implantation. The
first relapse site of the distant organs included the residual lung
in three patients with postoperative stage IIIB and the bone in
one patient with stage IIIA. At a median follow-up of 34months,
six patients have died. Of them, four patients died of cancer. Of
the remaining two patients, one died of pneumonia, whereas the
other died of a brain infarction. The Kaplan-Meier survival
according to the postoperative stage is shown in Figure 1. There
were no differences in survival between the lower (2–3) and
higher (4–6) groups of CCI score (p  0.2341).
Subset Analysis
In a subset analysis that excluded minor comorbidities
from the CCI, 30 patients with the CCI score of 2 or more
were analyzed. The subjects included six women (20.0%) and
24 men (80.0%). The median age was 72 years. The comor-
bid conditions included chronic pulmonary disease (n  15),
cerebrovascular disease (n  11), diabetes (n  8), ulcer
disease (n 8), liver disease (n 7), myocardial infarct (n
5), peripheral vascular disease (n  3), and hemiplegia (n 
1). The total score of the CCI was as follows: two in 24
patients, three in five patients, and four in one patient. The
median operation time was 315 minutes, and the bleeding
volume was 110 ml. The median length of hospitalization
was 14 days. The histologic types included adenocarcinoma
in 15 patients, squamous cell carcinoma in 14, and adeno-
squamous carcinoma in one. The postoperative stages were as
follows: IA in nine, IB in 12, IIB in one, IIIA in four, and IIIB
in four patients. There were 10 complications in eight patients
(26.7%). Postoperative complications included sputum reten-
tion requiring bronchoscopy (n 3, 10.0%), atrial fibrillation
(n  2, 6.7%), prolonged air leak (n  1, 3.3%), pleural
TABLE 2. Postoperative Complications (n  57)
Complication No. of Patients (%)
None 45 (78.9)
Air leak (lasting 7 d) 5 (8.8)
Atelectasis and/or sputum retention requiring
bronchoscopy
3 (5.3)
Atrial fibrillation 2 (3.5)
Late pleural effusion requiring thoracentesis 1 (1.8)
Pneumothorax 1 (1.8)
Chylothorax 1 (1.8)
Recurrent nerve injury 1 (1.8)
Two patients who had sputum retention requiring bronchoscopy developed multiple
complications.
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effusion (n 1), pneumothorax (n 1), chylothorax (n 1),
and recurrent nerve injury (n  1). There was no operative
mortality. The overall 5-year survival rates for postoperative
stage IA and IB were 100% and 91.7%, respectively.
DISCUSSION
There are two broadly applicable methods for rating
comorbid diseases. One is the method of Kaplan and Fein-
stein developed by consensual criteria for use in a longitudi-
nal study of patients with diabetes.19 The other is the CCI,17
which evolved the method of Kaplan and Feinstein. The CCI
excludes the following comorbid conditions as angina, ar-
rhythmia, hypertension, and severe obesity, which are in-
cluded in the Kaplan-Feinstein index, because their condi-
tions presented a low relative risk of death. Wang et al.3 have
suggested that the CCI has a great impact on the perioperative
mortality than the Kaplan-Feinstein index in patients with
stage I lung cancer. Thus, the CCI seems to be more reliable
than the Kaplan-Feinstein index because the comorbidity is
confined to only serious conditions. Birim et al.2 reported that
the CCI is a better predictor of survival than individual
comorbid conditions in lung cancer surgery. Asmis et al.4
suggested that the presence of comorbid conditions with the
CCI score of one or more was associated with a poor survival
in large prospective randomized trials of systemic chemother-
apy for NSCLC. Wang et al.3 demonstrated that patients with
the CCI score of 2 or more had higher perioperative mortality
compared with those with the CCI score of less than 2. Such
reports support the notion that patients with comorbidity can
be identified as those with a total CCI score of 2 or more in
this study. However, there remains a problem that a history of
a tumor such as prostatic cancer may be only a minor medical
issue, despite the high comorbidity score assigned to it. This
may be a subject of future investigation. The eligibility
criteria for surgery include the assessment of performance
status according to either the Karnofsky index or the Eastern
Cooperative Oncology Group performance scale. The CCI
offers a more objective measurement of the patient’s physi-
ologic reserve than the performance status because these
measures of performance status address the activity levels of
the patient and are often affected by the mental condition of
the patient.1
There are two reports on a VATS lobectomy for high-risk
patients. One is a case-control study designed comparison be-
tween VATS and an open thoracotomy,20 and the other is a case
series.21 Such reports have strongly affected the thoracic sur-
geons, although both studies were limited to showing short-term
survival in a small number of high-risk patients. When com-
pared with the high morbidity rate of 49 to 70% found in the
open thoracotomy studies of high-risk patients,22 the morbidity
of 15.8 to 46.2% of both studies of the VATS procedures is
favorable. Lower pain scores and decreased narcotic use asso-
ciated with VATS lobectomy may benefit high-risk patients.
Although the risk factors of our study patients may be lower than
those of the patients in the high-risk studies, our results of
morbidity (21.1%) and mortality (0%) are acceptable when
compared with those (15.3–22.6% and 0.5–1.8%, respectively)
of the many studies without explicit statements as to the surgical
risk of the study patients.8–15 Additionally, because a subset
analysis of high-risk patients in this study showed a satisfactory
morbidity (26.7%) and mortality (0%), a VATS lobectomy is
considered to be almost a safe procedure for NSCLC in patients
with comorbidity.
With respect to the number of dissected nodes, this study
using VATS obtained the same number or more nodes than the
other studies did by an open thoracotomy and achieved an
equivalent rate of lymphadenectomy-related morbidity, includ-
ing recurrent nerve injury and chylothorax.23 A randomized and
multiinstitutional study also showed that the complete medias-
tinal lymphadenectomy added little morbidity to a pulmonary
resection for lung cancer.24 The morbidity rate of this study is
acceptable for patients with comorbidity because of the absence
of serious complications and because of a lower morbidity than
that found in other studies using an open thoracotomy.23,24
Although several pulmonary complications often were found in
patients who had some pulmonary comorbidity, the number of
CCI score may not be associated with development of postop-
erative complication. Reduced bleeding volume, careful control
of air leak, neuroprotective procedures, and an effective phys-
iotherapy are considered to be needed to keep complications low
in high-risk patients.
The one conversion (1.8%) and postoperative hospitaliza-
tion (12 days) in this study are considered to be acceptable in
comparison with those (0–22.2% and 3–24 days, respectively)
of the many studies on VATS lobectomy for preoperative stage
I NSCLC, because this study included not only patients with
comorbidity but also nine patients (15.8%) with preoperative
FIGURE 1. Kaplan-Meier analysis of the overall survival after
a video-assisted thoracic surgery lobectomy for non-small
cell lung cancer according to the postoperative stage (log-
rank p  0.0071).
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stage II disease or greater. The length of stay after a VATS
lobectomy in this series was obviously shorter than the hospi-
talization (range, 32–115 days) after an open thoracotomy lo-
bectomy in our earlier study.23 Hospitalization generally tends to
be longer in Japan because the majority of patients are not
imposed with an excessive financial burden by the National
Health Insurance System.14
Both of the outcomes of local recurrence and of long-
term survival are believed to judge the oncological efficacy of
a VATS lobectomy for a NSCLC. Martini et al.25 demon-
strated local recurrence in 7% (systemic recurrence of 20%)
and a 5-year survival of 75% for stage I lung cancer (82% for
stage IA and 68% for stage IB) with an overall median
follow-up of 91 months in the open thoracotomy study (n 
598). The recurrence (0%) and 5-year survival rates (100%
for stage IA and 94% for stage IB) of comorbid patients with
postoperative stage I reported in this series of a VATS
lobectomy were compared favorably with those of the open
thoracotomy study, despite the smaller number of patients
with a shorter follow-up in our study. In comparison with the
outcomes dealing with similar surgery, our results also com-
pared favorably with those (recurrence rate, 2.6–27.4%;
5-year survival rate, 70.2–88.0% for stage IA, and 56.1–
77.0% for stage IB) without comorbidity published in other
reports. The patients with previous disease of malignancy
accounted for approximately 60% of all patients in this study.
In such patients, the latest lung cancer may be detected as a
consequence of cancer surveillance and therefore may be
found at an earlier stage. This could explain the high survival
in a risky population.
If the oncological efficacy of a VATS lobectomy can be
established, then this surgical procedure should also be ap-
plicable to patients with advanced stage NSCLC. Walker et
al.13 reported that a 5-year survival rate of stage III disease in
eight patients (stage IIIA in five and stage IIIB in three
patients) was 28.6%. McKenna et al.8 have shown a 5-year
survival of more than 30% in 109 patients with a postoper-
ative stage IIIA. It seems that a VATS approach does not
compromise the survival for patients with advanced stage
NSCLC, although the number of patients in this study was
small (Figure 1). Further study of advanced stage NSCLC
with a large number of patients and with a long-term onco-
logic follow-up is required.
In conclusion, we believe that a VATS lobectomy is
a feasible and safe procedure for NSCLC in patients with
comorbidity because it demonstrates an acceptable mor-
bidity and a favorable oncologic outcome, although the
limitations of this study includes the small number of
patients and the short term of observation. Independently
of CCI, a VATS lobectomy might be optimal for other
special populations including patients with orthopedic
problems, advanced age, and reduced performance status
caused by angina, arrhythmia, hypertension, and severe
obesity because of shorter hospitalizations, chest tube
durations, and earlier return to full preoperative activities
than an open lobectomy. Because this study population is
a series of complication-prone patients, the salutary effect
of VATS lobectomy should be magnified.
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